JMERC
Owner
Janbazan Medical and Engineering Research Center (JMERC) is the owner of IJWPH.
0.3
Cite Score
SJR: 0.114 / SNIP: 0.090
Volume 13, Issue 3 (2021)
Iran J War Public Health 2021, 13(3): 195-198 |
Back to browse issues page
Article Type:
Subject:
History
Received: 2021/08/16 | Accepted: 2021/08/5 | Published: 2021/11/10
Received: 2021/08/16 | Accepted: 2021/08/5 | Published: 2021/11/10
How to cite this article
Zaki Jafar Al-Asady A, Ali Hussein Al-Hilaly I. Using Vascular Cell Adhesion Molecule-1 as a Biomarker for Detecting Progression of Different Types of Malignant Tumors. Iran J War Public Health 2021; 13 (3) :195-198
URL: http://ijwph.ir/article-1-993-en.html
URL: http://ijwph.ir/article-1-993-en.html
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Rights and permissions
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Authors
A. Zaki Jafar Al-Asady1, I. Ali Hussein Al-Hilaly *2
1- Pharmacology and Toxicology Department, Faculty of Pharmacy, University of Kufa, Kufa, Iraq
2- Laboratory Investigation Department, Faculty of Science, University of Kufa, Kufa, Iraq
2- Laboratory Investigation Department, Faculty of Science, University of Kufa, Kufa, Iraq
Abstract (1926 Views)
Aims: Vascular cell adhesion molecule-1 is a transmembrane glycoprotein closely related to tumorigenicity as well as tumor metastasis. It is also a well-known candidate for detecting tumors as a very common consequence of war-related symptoms. This study was designed to investigate the probability of using a cancer biomarker (VCAM-1) as an indicator for the progression of breast, lung, and bladder cancers.
Materials & Methods: This experimental study was conducted on 15 to 89 years-old patients who attended the Middle Euphrates cancer center and the breast disease clinic in AL-Sadder Medical City teaching hospital in Al-Najaf Province, Iraq, for a checkup from September 2020 to January 2021. Eighty-eight samples were selected by random sampling method; 22 patients for each breast, lung, and bladder cancer group and 22 healthy subjects as control. An Enzyme-Linked Immunosorbent Assay (ELISA) was used to evaluate the concentration of VCAM-1. Data were analyzed by one-way ANOVA and Tukey's multiple comparison tests.
Findings: The means±SE of VCAM-1 levels in control, breast, lung, and bladder cancer groups were 42.29±3.928ng/ml, 58.12±2.357ng/ml, 66.81±4.307ng/ml, and 82.85±7.292ng/ml, respectively. Serum VCAM-1 levels increased significantly in all groups compared to the control group (p<0.05) except in breast cancer (p>0.05). There was a significant difference only between breast and bladder cancer groups (p<0.05).
Conclusion: The highest level of VCAM-1 is in the bladder cancer group; therefore, serum VCAM-1 can be used as an indicator for bladder cancer.
Materials & Methods: This experimental study was conducted on 15 to 89 years-old patients who attended the Middle Euphrates cancer center and the breast disease clinic in AL-Sadder Medical City teaching hospital in Al-Najaf Province, Iraq, for a checkup from September 2020 to January 2021. Eighty-eight samples were selected by random sampling method; 22 patients for each breast, lung, and bladder cancer group and 22 healthy subjects as control. An Enzyme-Linked Immunosorbent Assay (ELISA) was used to evaluate the concentration of VCAM-1. Data were analyzed by one-way ANOVA and Tukey's multiple comparison tests.
Findings: The means±SE of VCAM-1 levels in control, breast, lung, and bladder cancer groups were 42.29±3.928ng/ml, 58.12±2.357ng/ml, 66.81±4.307ng/ml, and 82.85±7.292ng/ml, respectively. Serum VCAM-1 levels increased significantly in all groups compared to the control group (p<0.05) except in breast cancer (p>0.05). There was a significant difference only between breast and bladder cancer groups (p<0.05).
Conclusion: The highest level of VCAM-1 is in the bladder cancer group; therefore, serum VCAM-1 can be used as an indicator for bladder cancer.
Keywords:
References
1. Duffy MJ. Clinical use of tumor biomarkers: An overview. Klin Biochem Metab. 2017;25(4):157-61. []
2. Zhang X, Liu C, Hu F, Zhang Y, Wang J, Gao Y, et al. PET imaging of VCAM-1 expression and monitoring therapy response in tumor with a 68 Ga-labeled single chain variable fragment. Mol Pharm. 2018;15(2):609-18. [] [DOI:10.1021/acs.molpharmaceut.7b00961] [PMID]
3. Kong DH, Kim YK, Kim MR, Jang JH, Lee S. Emerging roles of vascular cell adhesion molecule-1 (VCAM-1) in immunological disorders and cancer. Int J Mol Sci. 2018;19(4):13-7. [] [DOI:10.3390/ijms19041057] [PMID] [PMCID]
4. Liu YS, Lin HY, Lai SW, Huang CY, Huang BR, Chen PY, et al. MIR-181b modulates EGFR-dependent VCAM-1 expression and monocyte adhesion in glioblastoma. Oncogene. 2017;36(35):5006-22. [] [DOI:10.1038/onc.2017.129] [PMID]
5. Montemagno C, Dumas L, Cavailles P, Ahmadi M, Bacot S, Debiossat M, et al. In vivo assessment of VCAM-1 expression by SPECT/CT imaging in mice models of human triple negative breast cancer. Cancers. 2019;11(7):1039. [] [DOI:10.3390/cancers11071039] [PMID] [PMCID]
6. Sharma R, Sharma R, Khaket TP, Dutta C, Chakraborty B, Mukherjee TK. Breast cancer metastasis: Putative therapeutic role of vascular cell adhesion molecule-1. Cell Oncol. 2017;40(3):199-208. [] [DOI:10.1007/s13402-017-0324-x] [PMID]
7. Thakkar V, Patterson KA, Stevens W, Wilson M, Roddy J, Sahhar J, et al. Increased serum levels of adhesion molecules ICAM-1 and VCAM-1 in systemic sclerosis are not specific for pulmonary manifestations. Clin Rheumatol. 2018;37(6):1563-71. [] [DOI:10.1007/s10067-018-4081-7] [PMID]
8. Mirdan RAAR. Levels of some cellular adhesion molecules (CEA, sICAM-1, sVCAM-, and E- selecting) in patients affected with colon and urinary bladder cancer during pre and post-operative surgery. Ann Trop Med Public Health. 2020;23(24):1-11. [] [DOI:10.36295/ASRO.2020.232439]
9. Zhang D, Bi J, Liang Q, Wang S, Zhang L, Han F, et al. VCAM1 promotes tumor cell invasion and metastasis by inducing EMT and Transendothelial migration in colorectal cancer. Front Oncol. 2020;10:1066. [] [DOI:10.3389/fonc.2020.01066] [PMID] [PMCID]
10. Kim MR, Jang JH, Park CS, Kim TK, Kim YJ, Chung J, et al. A human antibody that binds to the sixth Ig-like domain of VCAM-1 blocks lung cancer cell migration in vitro. Int J Mol Sci. 2017;18(3):566. [] [DOI:10.3390/ijms18030566] [PMID] [PMCID]
11. Chang AC, Chen PC, Lin YF, Su CM, Liu JF, Lin TH, et al. Osteoblast-secreted WISP-1 promotes adherence of prostate cancer cells to bone via the VCAM-1/integrin α4β1 system. Cancer Lett. 2018;426:47-56. [] [DOI:10.1016/j.canlet.2018.03.050] [PMID]